Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.2800 (-1.49%) ($5.2500 - $5.5800) on Tue. Nov. 13, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.61% (three month average) | RSI | 56 | Latest Price | $5.2800(-1.49%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) GDXJ(4%) XHB(4%) DIA(3%) VCSH(3%) BNDX(2%) | Factors Impacting TGTX price | TGTX will decline at least -3.305% in a week (0% probabilities). XBI(-5%) URA(-5%) OIH(-5%) XOP(-4%) XLE(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.305% (StdDev 6.61%) | Hourly BBV | 0 () | Intraday Trend | -1.9% | | | |
|
5 Day Moving Average | $5.36(-1.49%) | 10 Day Moving Average | $5.16(2.33%) | 20 Day Moving Average | $5.1(3.53%) | To recent high | -58.4% | To recent low | 4.1% | Market Cap | $669m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |